Pancreatic cancer drug shows early promise against lung cancer

A small trial of daraxonrasib (Rasonque) in non-small-cell lung cancer with RAS mutations showed tumor shrinkage in more than 30% of participants, signaling potential beyond pancreatic cancer. A larger randomized trial is under way to confirm efficacy and durability, with regulatory decisions pending. The drug, which had already received FDA approval for pancreatic cancer after earlier successes, works as a molecular glue that exposes RAS to inhibition via cyclophilin A, a mechanism that could extend to other hard-to-treat tumors, though resistance can emerge.